Rheumatoid Arthritis Trial, Recruiting NCT05927688 Sponsor: University Hospital, Strasbourg, France Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Rheumatoid Arthritis Trial, Recruiting

NCT05927688
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man or woman aged 18 or older
  • You have been diagnosed with at least one of the following conditions: Rheumatoid Arthritis, Gout, Systemic Lupus Erythematosus, or Sjögren's Syndrome (diagnosed using specific standard medical guidelines — confirm with trial site)
  • You have agreed to take part in the study, either by signing a written consent form (in Switzerland or Germany) or by formally not objecting to participation (in France)
  • You have access to the internet, a working email address, and a mobile phone number
  • You are physically and mentally able to use an internet-connected computer or device
  • If you are in Switzerland or Germany, you are covered by a health insurance plan

Who may not be able to join:

  • You have a neurodegenerative disease (a condition that progressively affects brain function, such as Alzheimer's disease) that affects your thinking or memory
  • You have an active, treatment-resistant cancer
  • You do not have internet access or are not comfortable using the internet as required by this study
  • You are unwilling or unable to follow the study's rules and procedures (for example, due to language difficulties or cognitive challenges)
  • You are currently held under a compulsory psychiatric treatment order
  • You cannot be monitored by the study doctor for the full 2-year study period
  • You are a legally protected adult or someone whose freedom has been restricted by a court or government decision (confirm with trial site)
  • Your estimated life expectancy is less than 1 year

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 3 88 12 79 53

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
18 July 2023
Est. completion
1 July 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Frequency of therapeutic adjustments

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov